Why do patients still require surgery for the late complications of Proliferative Diabetic Retinopathy

Eye

Volumn 24, Issue 3, 2010, Pages 435-440

  Scanlon, P H ^a  

^a CHELTENHAM GENERAL HOSPITAL   (United Kingdom)

Author keywords

Diabetic retinopathy; Neovascular glaucoma; Screening; Vitrectomy

Indexed keywords

VASCULOTROPIN INHIBITOR;

BLOOD GLUCOSE MONITORING; BLOOD PRESSURE REGULATION; CLINICAL TRIAL; CONFERENCE PAPER; DEPRESSION; DIABETIC RETINOPATHY; DISEASE CONTROL; DISEASE COURSE; DISEASE DURATION; EATING DISORDER; ETHNIC DIFFERENCE; EYE DISEASE; GENETIC PREDISPOSITION; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; IRIS RUBEOSIS; LOW LEVEL LASER THERAPY; NEOVASCULAR GLAUCOMA; PSYCHOLOGICAL ASPECT; RISK FACTOR; RISK REDUCTION; SCREENING; SMOKING CESSATION; STAGING; TREATMENT INDICATION; VITRECTOMY;

EID: 77949452024     PISSN: 0950222X     EISSN: 14765454     Source Type: Journal    
DOI: 10.1038/eye.2009.320     Document Type: Conference Paper

References (50)

1. The Liverpool Declaration 2005, Report of Conference. Screening for Diabetic Retinopathy in Europe 15 years after the St Vincent Declaration; 2005 17th-18th November 2005; Liverpool http://www.drscreening2005.org.uk/ conference-report.doc.
2. Helbig H. Surgery for diabetic retinopathy. Ophthalmologica 2007; 221(2): 103-111.
3. Joussen AM, Joeres S. Benefits and limitations in vitreoretinal surgery for proliferative diabetic retinopathy and macular edema. Dev Ophthalmol 2007; 39: 69-87.
4. Blankenship GW, Machemer R. Long-term diabetic vitrectomy results. Report of 10 year follow-up. Ophthalmology 1985; 92(4): 503-506.
5. Thompson JT, de Bustros S, Michels RG, Rice TA, Glaser BM. Results of vitrectomy for proliferative diabetic retinopathy. Ophthalmology 1986; 93(12): 1571-1574.
6. Lahey JM, Francis RR, Kearney JJ. Combining phacoemulsification with pars plana vitrectomy in patients with proliferative diabetic retinopathy: a series of 223 cases. Ophthalmology 2003; 110(7): 1335-1339.
7. Yorston D, Wickham L, Benson S, Bunce C, Sheard R, Charteris D. Predictive clinical features and outcomes of vitrectomy for proliferative diabetic retinopathy. Br J Ophthalmol 2008; 92(3): 365-368.
8. Klein R, Klein BE, Moss SE, Davis MD, DeMets DL. The Wisconsin Epidemiologic Study of Diabetic Retinopathy. IX. Four-year incidence and progression of diabetic retinopathy when age at diagnosis is less than 30 years. Arch Ophthalmol 1989; 107(2): 237-243.
9. Klein R, Klein BE, Moss SE, Davis MD, DeMets DL. The Wisconsin Epidemiologic Study of Diabetic Retinopathy. X. Four-year incidence and progression of diabetic retinopathy when age at diagnosis is 30 years or more. Arch Ophthalmol 1989; 107(2): 244-249.
10. Klein R, Klein BE, Moss SE, Davis MD, DeMets DL. The Wisconsin epidemiologic study of diabetic retinopathy. II. Prevalence and risk of diabetic retinopathy when age at diagnosis is less than 30 years. Arch Ophthalmol 1984; 102(4): 520-526.
11. Klein R, Klein BE, Moss SE, Davis MD, DeMets DL. The Wisconsin epidemiologic study of diabetic retinopathy. III. Prevalence and risk of diabetic retinopathy when age at diagnosis is 30 or more years. Arch Ophthalmol 1984; 102(4): 527-532.
12. Klein R, Klein BE, Moss SE, Cruickshanks KJ. The Wisconsin Epidemiologic Study of diabetic retinopathy. XIV. Ten-year incidence and progression of diabetic retinopathy. Arch Ophthalmol 1994; 112(9): 1217-1228.
13. Stratton IM, Kohner EM, Aldington SJ, Turner RC, Holman RR, Manley SE et al. UKPDS 50: risk factors for incidence and progression of retinopathy in Type II diabetes over 6 years from diagnosis. Diabetologia 2001; 44(2): 156-163.
14. Hietala K, Forsblom C, Summanen P, Groop PH. Heritability of proliferative diabetic retinopathy. Diabetes 2008; 57(8): 2176-2180.
15. Emanuele N, Sacks J, Klein R, Reda D, Anderson R, Duckworth W et al. Ethnicity, race, and baseline retinopathy correlates in the veterans affairs diabetes trial. Diabetes Care 2005; 28(8): 1954-1958.
16. Simmons D, Clover G, Hope C. Ethnic differences in diabetic retinopathy. Diabet Med 2007; 24(10): 1093-1098.
17. Flynn Jr HW, Chew EY, Simons BD, Barton FB, Remaley NA, Ferris III FL. Pars plana vitrectomy in the Early Treatment Diabetic Retinopathy Study. ETDRS report number 17. The Early Treatment Diabetic Retinopathy Study Research Group. Ophthalmology 1992; 99(9): 1351-1357.
18. Early vitrectomy for severe vitreous hemorrhage in diabetic retinopathy. Two-year results of a randomized trial. Diabetic Retinopathy Vitrectomy Study report 2. The Diabetic Retinopathy Vitrectomy Study Research Group. Arch Ophthalmol 1985; 103(11): 1644-1652.
19. Early vitrectomy for severe vitreous hemorrhage in diabetic retinopathy. Four-year results of a randomized trial: Diabetic Retinopathy Vitrectomy Study Report 5. Arch Ophthalmol 1990; 108(7): 958-964.
20. Meier P, Wiedemann P. Vitrectomy for traction macular detachment in diabetic retinopathy. Graefes Arch Clin Exp Ophthalmol 1997; 235(9): 569-574.
21. Thompson JT, de Bustros S, Michels RG, Rice TA. Results and prognostic factors in vitrectomy for diabetic tractionrhegmatogenous retinal detachment. Arch Ophthalmol 1987; 105(4): 503-507.
22. Favard C, Guyot-Argenton C, Assouline M, Marie-Lescure C, Pouliquen YJ. Full panretinal photocoagulation and early vitrectomy improve prognosis of florid diabetic retinopathy. Ophthalmology 1996; 103(4): 561-574.
23. Laidlaw DA. Vitrectomy for diabetic macular oedema. Eye 2008; 22(10): 1337-1341.
24. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The diabetes control and complications trial research group. N Engl J Med 1993; 329(14): 977-986.
25. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS33). UK Prospective Diabetes Study (UKPDS) Group. Lancet 1998; 352(9131): 837-853.
26. Chase HP, Garg SK, Jackson WE, Thomas MA, Harris S, Marshall G et al. Blood pressure and retinopathy in type I diabetes. Ophthalmology 1990; 97(2): 155-159.
27. Matthews DR, Stratton IM, Aldington SJ, Holman RR, Kohner EM. Risks of progression of retinopathy and vision loss related to tight blood pressure control in type 2 diabetes mellitus: UKPDS 69. Arch Ophthalmol 2004; 122(11): 1631-1640.
28. Chew EY, Klein ML, Ferris 3rd FL, Remaley NA, Murphy RP, Chantry K et al. Association of elevated serum lipid levels with retinal hard exudate in diabetic retinopathy. Early Treatment Diabetic Retinopathy Study (ETDRS) Report 22. Arch Ophthalmol 1996; 114(9): 1079-1084.
29. Cusick M, Chew EY, Chan CC, Kruth HS, Murphy RP, Ferris III FL. Histopathology and regression of retinal hard exudates in diabetic retinopathy after reduction of elevated serum lipid levels. Ophthalmology 2003; 110(11): 2126-2133.
30. Karamanos B, Porta M, Songini M, Metelko Z, Kerenyi Z, Tamas G et al. Different risk factors of microangiopathy in patients with type I diabetes mellitus of short versus long duration. The EURODIAB IDDM Complications Study. Diabetologia 2000; 43(3): 348-355.
31. DeNavas-Walt C, Proctor BD, Smith J. Income, Poverty, and Health Insurance Coverage in the United States: 2006. US Census Bureau: Washington, 2007. p 59.
32. Zoega GM, Gunnarsdottir T, Bjornsdottir S, Hreietharsson AB, Viggosson G, Stefansson E. Screening compliance and visual outcome in diabetes. Acta Ophthalmol Scand 2005; 83(6): 687-690.
33. Gray RH, Blades C, Jobson C. Screening clinic nonattendance and the risk of sight threatening retinopathy. Eur J Ophthalmol 2009; 19(3): 510.
34. Scanlon PH, Carter SC, Foy C, Husband RF, Abbas J, Bachmann MO. Diabetic retinopathy and socioeconomic deprivation in Gloucestershire. J Med Screen 2008; 15(3): 118-121.
35. Gale EA. How to survive diabetes. Diabetologia 2009; 52: 559-567.
36. Szydlo D, van Wattum PJ, Woolston J. Psychological aspects of diabetes mellitus. Child Adolesc Psychiatr Clin N Am 2003; 12(3): 439-458, vi.
37. Rose M, Fliege H, Hildebrandt M, Schirop T, Klapp BF. The network of psychological variables in patients with diabetes and their importance for quality of life and metabolic control. Diabetes Care 2002; 25(1): 35-42.
38. Weinger K, Jacobson AM. Psychosocial and quality of life correlates of glycemic control during intensive treatment of type 1 diabetes. Patient Educ Couns 2001; 42(2): 123-131.
39. Schram M, Baan C, Pouwer F. Depression and quality of life in patients with diabetes: a systematic review from the european depression in diabetes (EDID) research consortium. Curr Diabetes Rev 2009; 5(2): 112-119.
40. Gastaldi G, Ruiz J, Giusti V. Patient with type 2 diabetes: don't forget eating disorders!. Rev Med Suisse 2009; 5(196): 667-670.
41. Goebel-Fabbri AE, Fikkan J, Connell A, Vangsness L, Anderson BJ. Identification and treatment of eating disorders in women with type 1 diabetes mellitus. Treat Endocrinol 2002; 1(3): 155-162.
42. Goebel-Fabbri AE. Disturbed eating behaviors and eating disorders in type 1 diabetes: clinical significance and treatment recommendations. Curr Diab Rep 2009; 9(2): 133-139.
43. Reddy VM, Zamora RL, Olk RJ. Quantitation of retinal ablation in proliferative diabetic retinopathy. Am J Ophthalmol 1995; 119(6): 760-766.
44. Bailey CC, Sparrow JM, Grey RH, Cheng H. The National Diabetic Retinopathy Laser Treatment Audit. III. Clinical outcomes. Eye 1999; 13(Part 2): 151-159.
45. Bailey CC, Sparrow JM, Grey RH, Cheng H. The National Diabetic Retinopathy Laser Treatment Audit. II. Proliferative retinopathy. Eye 1998; 12(Part 1): 77-84.
46. Nahberger D, Meyer-Schwickerath R, Saygili O, Gronemeyer U. Development of neovascularization of the optic papilla, retina and iris. Dependence on site and extent of retinal ischemia. Ophthalmologe 2000; 97(6): 422-428.
47. Hayakawa K. Outcome of vitrectomy for proliferative diabetic retinopathy with iris or angle rubeosis. Japanese J Clin Ophthalmol 2006; 60(5): 797-800.
48. Nabili S, Kirkness CM. Trans-scleral diode laser cyclophotocoagulation in the treatment of diabetic neovascular glaucoma. Eye 2004; 18(4): 352-356.
49. Oshima Y, Sakaguchi H, Gomi F, Tano Y. Regression of iris neovascularization after intravitreal injection of bevacizumab in patients with proliferative diabetic retinopathy. Am J Ophthalmol 2006; 142(1): 155-158.
50. Jiang Y, Liang X, Li X, Tao Y,Wang K. Analysis of the clinical efficacy of intravitreal bevacizumab in the treatment of iris neovascularization caused by proliferative diabetic retinopathy. Acta Ophthalmol 2008; 27(7): 7236-7240.